StockData

Lensar vs Sight Sciences

LNSR and SGHT side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LNSR and SGHT compare

Sight Sciences is the larger company, worth 10.0 times as much as Lensar ($593M against $59.6M).

Sight Sciences grew revenue faster over the last twelve months (9.3% versus 3.3% for Lensar).

Lensar keeps more of each dollar of sales as profit, with a net margin of 57.6% compared with −35.7% at Sight Sciences.

Lensar scores higher on the StockData Score (8 against 4 for Sight Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLNSRSGHT
Size and price
Market cap$59.6M$593M
Share price$4.85$10.77
Change, 1 year−50.8%53.2%
Change, 5 years−30.9%−43.6%
Beta (5Y)0.591.97
Employees150186
StockData Score
Total score8 (better)4
Valuation score2 (better)0
Growth score22
Performance score2 (better)1
Health score2 (better)1
Dividend score00
Valuation
P/S1.0× (better)7.1×
P/B4.0× (better)11.2×
FCF yield–−3.9%
Fair value$6.27$3.93
Margin of safety22.7% (better)−174%
Growth
Revenue growth (TTM)3.3%9.3% (better)
Revenue growth, 5Y average17.2%22.9% (better)
Profitability
Gross margin48.3%88.0% (better)
Operating margin−13.5% (better)−33.4%
Net margin57.6% (better)−35.7%
FCF margin–−28.0%
Return on equity–−48.4%
Return on invested capital–−136%
Financial health
Debt / equity0.25 (better)0.96
Interest coverage–−5.4×
Current ratio2.394.95 (better)
Altman Z-score−0.942.32 (better)
Piotroski F-score35 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions36.0%40.2%
Held by insiders–33.1%
Insider net buying, 12 months–−$2.2M
Short interest, % of float–3.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.